<DOC>
	<DOCNO>NCT02360020</DOCNO>
	<brief_summary>Stent delivery failure occur 4 % percutaneous coronary intervention ( PCI ) &gt; 90 % failure due vessel tortuosity and/or calcification . The XLIMUS elute coronary stent ( CARDIONOVUM GmbH , Bonn , Germany ) new type endovascular prosthesis characterise well mechanical property traditional DES . This prospective , non-randomized , single-center pilot study , aim evaluate performance XLIMUS DES severely complex coronary lesion real-world clinical practice .</brief_summary>
	<brief_title>The XLIMUS-DES Very Complex Lesions</brief_title>
	<detailed_description>All consecutive patient undergo elective PCI native coronary artery Clinica Mediterranea ( Naples , Italy ) consider eligility . Study participant wiil require symptomatic ischemic heart disease attributable critical ( , &gt; 70 % visual estimate ) stenotic lesion native coronary artery . Inclusion criterion pilot study 1 ) chronic total occlusion ( CTO ) , 2 ) severe target vessel calcification , 3 ) severe target vessel tortuosity . CTO define presence TIMI 0 flow within occluded segment angiographic clinical evidence high likelihood occlusion duration ≥3 month . Calcification define severe large 3x vessel diameter , comprise vessel wall totally two perpendicular view . Tortuosity define severe satisfies follow criterion : one bend 90° , three bend 45-90° proximal diseased segment . 200 patient enrol study . Stents implant accord current clinical practice . Techniques attempt facilitate stent delivery complex lesion : maximize guide catheter support , optimize predilatation stenosis , use stiffer guidewire . Specific trick include : ) buddy-wire ; anchor balloon ; GuideLiner catheter . In case severe calcification , rotational atherectomy electively perform Rotablator® system ( Boston Scientific Corporation , Natick , MA , U.S.A. ) . Following stent implantation , postdilatation perform instance non-compliant balloon . All patient receive aspirin 325 mg clopidogrel ( 75 mg daily ) stent deployment , load dose ( 600 mg clopidogrel ) give patient pretreated . All patient receive 70 IU/Kg intra-arterial bolus unfractionated heparin order achieve activate clotting time &gt; 250 second . Glycoprotein IIb/IIIa inhibitor administer accord operator preference . Estimated glomerular filtration rate ( eGFR ) calculate apply Levey Modification Diet Renal Disease ( MDRD ) formula . Chronic kidney disease define eGFR &lt; 60 ml/min/1.73 m2 . XLIMUS eluting-stent make cobalt chromium L 605 stent available 6- , 8- , 10-cell structure design ( close cell architecture ) . The struts thickness 73µm . The 6-cell design stenting coronary artery diameter 2.25mm-2.50mm , 8-cell structure use stenting 2.75-3.50 mm artery diameter , 10-cell large artery diameter lesion ( 5mm ) . The XLIMUS innovative hydrophilic-coated shaft extra-low tip profile ( cross profile = 0.90 mm ) access tortuous lesion . The highly biocompatible polylactid acid ( PLLA ) drug contain release matrix degrade smoothly provide optimal release kinetic profile . Within 30 day , 70 % anti-proliferative drug distribute surround arterial tissue stent strut , ensure highly effective inhibition smooth muscle cell migration proliferation . Pharmacokinetic study result confirm sustain anti-proliferative drug efficacy 120 day . The primary objective study assessment clinical performance XLILMUS DES , use follow criterion 1 ) device success , define ability insert stent target lesion attainment &lt; 20 % residual stenosis ( visual estimate ) , 2 ) lesion success , define attainment &lt; 20 % residual stenosis target lesion use percutaneous method , 3 ) procedural success , define lesion success without in-hospital MACE .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<criteria>chronic total occlusion ( CTO ) severe calcification severe tortuosity • coronary artery lesion non satisfy inclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>coronary stent</keyword>
	<keyword>outcome</keyword>
</DOC>